friday, September 26, 2025
| Agenda | |
|---|---|
| Session 1: TIL and Transgenic TCR-based Therapies | |
| Anti-Minor Histocompatibility Antigen And Anti-Neoantigen T Cells in Treatment of Cancer Warren Shlomchik, MD University of Pittsburgh | |
| Personalized TCR-engineered Therapies for Head and Neck Cancer Joseph Zenga, MD Medical College of Wisconsin | |
| Jonas Memorial Keynote Lecture | |
| CARs and Armored CARs: T cells for Cancer Therapy Renier Brentjens, MD, PhD Roswell Park Comprehensive Cancer Center | |
| Session 2: Understanding Complications of Cellular Therapy | |
| Cytokine Release Syndrome following Chimeric Antigen Receptor T Cell Therapy: Mechanism and Mitigation Michael Slade, MD WashU Medicine | |
| CAR T Cells and the Brain Juliane Gust, MD, PhD Seattle Children’s/University of Washington | |
| Janet Rowley Keynote Lecture | |
| CAR T cell therapy for Acute Myeloid Leukemia Saar Gill, MD, PhD University of Pennsylvania | |
| Session 3: Novel Cellular Therapies- From Bench to Bedside | |
| Development of BAFFRCAR T cell therapy in B Lymphoid Malignancy Elizabeth Budde, MD, PhD City of Hope | |
| Improving Specificity and Reducing Exhaustion Using A Prime-and-Kill CAR-T Strategy Jennifer Clarke, MD, MPH University of California San Francisco | |
| Session 4: Cellular and Gene Therapy for Classical Hematology: Progress and Challenges Ahead | |
| Gene therapy for Sickle Cell Disease Mitchell Weiss, MD, PhD St. Jude Children’s Research Hospital | |
| What is the Current Clinical Utility of Gene Therapy for Sickle Cell Disease James LaBelle, MD, PhD University of Chicago | |
| High stakes: Why being a FINANCIAL Center of Excellence is critical to program success Stephanie Farnia, MPH Nimitt Consulting |